Targeting Metabolic Reprograming in Oncology & Fibrosis
ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to advance novel anti-cancer and/or anti-fibrosis therapies to patients. Our lead molecule, lixumistat (IM156), is an orally bioavailable small molecule protein complex 1 (PC1) inhibitor that targets Oxidative Phosphorylation (OxPhos) and decreases aberrant cell growth and proliferation in targeted cancer cells and fibrosis. The company has characterized lixumistat in Phase 1 dose escalation and food effect studies in healthy subjects as well as in a dose escalation study in patients with advanced solid tumors. Together, these studies have provided characterization of the pharmacokinetics and safety profile of lixumistat over a broad dose range and have demonstrated target inhibition in healthy human subjects with once-daily dosing. Lixumistat is the first PC1 inhibitor to complete Phase 1 with good tolerability.
ImmunoMet Therapeutics, founded in 2015 as a spin-off from the Korean company HanAll Biopharma, owns a large library of biguanides with the potential for development, internally or with partners, as novel treatments for cancer and/or diseases of fibrosis. The company, headquartered in JLABS @ TMC in Houston has raised $39 MM since its inception.